Open AccessHigh Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
Author(s) -
Farshad Guirakhoo,
Shixia Wang,
Chang Yi Wang,
Hsu-Ko Kuo,
Wen Jiun Peng,
Hope Liu,
Lixia Wang,
Marina Johnson,
Adam Hunt,
Mei Mei Hu,
Thomas P. Monath,
Alexander Rumyantsev,
David Green
Publication year - 2022
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiac241
Subject(s) - antibody , virology , neutralizing antibody , coronavirus , booster (rocketry) , vaccination , booster dose , respiratory system , covid-19 , medicine , immunology , biology , disease , infectious disease (medical specialty) , immunization , physics , astronomy
The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.